Compare Ferrari NV (RACE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs State Street SPDR S&P Biotech ETF — how do they compare? Ferrari NV trades at $389.91 (market cap $67.35B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Ferrari NV is far larger — about 6.7× State Street SPDR S&P Biotech ETF's market cap, and Ferrari NV pays a 1.09% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RACE | XBI | |
|---|---|---|
Market Cap | $67.35B | $10.11B |
Volume | 390,618 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $436.54 | $169.55 |
52-Week Low | $314.63 | $104.99 |
Typical Hold Time | 126 Days | 38 Days |
Enterprise Value | $69.22B | — |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15B in 2025, with a net income margin of 22.25% and robust ROE of 45.45%. The company is executing a share buyback program and recently announced a partnership with Rakuten effective January 2027.
The outlook is positive given strong profitability, consistent earnings beats, and analyst consensus favoring a buy rating with a $462.75 price target. Risks include high valuation multiples (P/E 37.19) and exposure to economic cycles affecting luxury demand. Institutional buying and buyback support provide downside cushion, but investors should monitor execution on future growth initiatives.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
